Mergers & Acquisitions ·
SEC declares effective the $1.5B merger of Scipher Medicine into Chemomab Therapeutics
CMMBChemomab Therapeutics Ltd.
The Securities and Exchange Commission declared effective an amendment to the Registration Statement on Form S-4 for a proposed business combination between Chemomab Therapeutics Ltd. and Scipher Medicine Corporation. The transaction involves Chemomab redomiciling to the United States, with Scipher becoming a wholly owned subsidiary. This filing incorporates by reference key sections of the registration statement, including audited financial statements for Scipher and Chemomab, management discussion and analysis, and unaudited pro forma condensed combined financial information reflecting the merger. The deal represents a significant strategic consolidation in the biotechnology sector.